SCHEMBL22650586

SCHEMBL22650586

COc1nc(-c2nc(Cl)ncc2F)cc2c1nc(C)n2C(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 3/20 0.39
CDK4 P11802 18/20 0.37
CDK6 Q00534 15/20 0.37
CCND3 P30281 8/20 0.37
CCND1 P24385 7/20 0.37
CDK2 P24941 9/20 0.37
CDK1 P06493 7/20 0.36
CCNB1 P14635 4/20 0.36
CCNA2 P20248 2/20 0.36
KDR P35968 2/20 0.36
CDK7 P50613 4/20 0.35
CDK9 P50750 4/20 0.35
CCNE1 P24864 3/20 0.35
CIT O14578 1/20 0.35
GAK O14976 1/20 0.35
DYRK3 O43781 1/20 0.35
CCNT1 O60563 1/20 0.35
STK16 O75716 1/20 0.35
CCNK O75909 1/20 0.35
STK10 O94804 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22650829 0.89 CDK4 (0.34) EGFRCDK4CDK6CCND3CCND1
SCHEMBL22650828 0.89 CDK4 (0.33) EGFRCDK4CDK6CCND3CCND1
SCHEMBL22650358 0.89 EGFR (0.33) EGFRCDK4CDK6CCND3CCND1
SCHEMBL22650826 0.83 AAK1 (0.38) EGFRCDK4CDK6CCND3CCND1
SCHEMBL22650721 0.81 SMN1; SMN2 (0.34) CDK4CDK6CCND3CCND1CDK2
SCHEMBL22650827 0.79 CDK4 (0.39) EGFRCDK4CDK6CCND3CCND1
SCHEMBL2514899 0.78 CDK4 (0.55) EGFRCDK4CDK6CCND3CCND1
SCHEMBL29669654 0.78 CDK4 (0.55) EGFRCDK4CDK6CCND3CCND1
SCHEMBL22650399 0.76 CDK4 (0.33) CDK4CDK6CCND3CCND1CDK2
SCHEMBL20987199 0.76 CDK4 (0.53) EGFRCDK4CDK6CCND3CCND1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120040446-A CDK inhibitors 基因泰克公司 2025-05-27 CN disclosed
US-20220296595-A1 CDK INHIBITORS GENENTECH, INC. 2022-09-22 US disclosed
EP-3966213-A1 CDK INHIBITORS Qilu Regor Therapeutics Inc. (CN) 2022-03-16 EP disclosed
WO-2020224568-A1 CDK INHIBITORS QILU REGOR THERAPEUTICS INC. (CN) 2020-11-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220296595-A1 CDK INHIBITORS CDKL1, CDK9, CDK6 EGFR 867/4885CDK4 10/4885CDK6 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.